NGM·Healthcare·$289M·#434 / 520 in Healthcare
TRDA Entrada Therapeutics, Inc.
24HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY44
VALUATION0
GOVERNANCE76
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-87.9%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
8 months
22
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
16.6%
87
< 25% strong
Price / Sales
Market cap relative to trailing revenue
50.4x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-709
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
12.3%
70
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.1%
88
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE TRDA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when TRDA's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.